ライフサイエンスコーパス: isoxazole

1 1,3-diketone moiety masked in the form of an isoxazole.

2 tituents at the 3, 4, and 5 positions of the isoxazole.

3 f the desired 4-alkenyl-3,4,5-trisubstituted isoxazoles.

4 odium vinylcarbenoids across the N-O bond of isoxazoles.

5 of aryl iodides affords 3,4,5-trisubstituted isoxazoles.

6 st-8-en-3-one (10) give predominantly [3,2-c]isoxazoles.

7 (beta,beta,beta-trifluoro-alpha-hydroxyethyl)isoxazoles.

8 n be synthesized in a one-pot procedure from isoxazoles.

9 ew glycosyl triazoles and aryl triazoles and isoxazoles.

10 thiooxoaminothiazoles, and pyrazole-pyrrole-isoxazoles.

11 -methyl-1H-benzotriazole 5, 3-methyl-benzo[d]isoxazole 3, and 3-methyl-[1,2,4]triazolo[4,3-a]pyridine

12 3,5-bis(4-amidinophenyl)isoxazole (3)-an analogue of 2,5-bis(4-amidinophenyl)fur

13 ely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 7a and N-(pyridin-2-yl)-5-(2-(p-

14 yridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 8a, were found to show high inhi

15 l- N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[ d]isoxazole-3-carboxamide derivatives as novel potent Myco

16 potent 5-(2-methylbenzothiazol-5-yloxymethyl)isoxazole-3-carboxamide derivatives, which proved to be

17 8-bis(trifluoromethyl)quinolin-4-yloxymethyl)isoxazole-3-carboxylic acid ethyl ester (compound 3) wit

18 ough 5-HT(2A) and/or 5-HT(2C) receptors, the isoxazoles 3d and 4d constitute interesting leads for fu

19 H) acetates into alkyl 3-nitro-5-(aryl/alkyl)isoxazole-4-carboxylates is described.

20 The first synthesis of isoxazole-4-carboxylic acid derivatives by domino isoxaz

21 ne, 105 degrees C) leads to the formation of isoxazole-4-carboxylic esters and amides in good yields.

22 activation of alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate/kainate (AMPA/KA) and NMDA recept

23 necrotically in an -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptor-dependent man

24 C termini of alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptors in vitro and

25 artic acid or alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA)-subtype glutamate rece

26 AMPAR (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptor) is an ion channel i

27 postsynaptic alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs) prevents L

28 mpal neurons, alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid subtype glutamate receptor (A

29 ate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) and kainate receptors; criti

30 following AMPA (DL-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid) receptor activation.

31 for agonist (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid)-initiated rapid proteolytic

32 The isoxazol-3-one tautomer of the bicyclic isoxazole, 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-

33 Reaction of isoxazole-5-carbaldehydes with the Ruppert-Prakash reage

34 Isoxazole 6d demonstrated impressive efficacy when admin

35 evious work with a synthetic small molecule, isoxazole 9 (Isx-9), highlighted its neuronal-differenti

36 Systemic treatment with the drug Isoxazole-9 (a synthetic small molecule known to modulat

37 Isoxazole-9 modulated neurogenesis, neuronal activation

38 injury, and treatment of dermal wounds with isoxazole accelerates wound closure and suppresses the i

39 itor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) inhibited huM

40 d to (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an inhibitor

41 y of (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), an orally bi

42 and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1).

43 nist (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester considerably attenuat

44 O-1 ((S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester)," significantly inhi

45 nctionality of UPOC methyl ester with a free isoxazole acid using HBTU or alternatively an isoxazole

46 nd the enyne gave the rare 3,4-disubstituted isoxazole adduct under kinetic reaction conditions.

47 d N,N-dialkylamino-3-aryl/alkyl-4-(2-R-vinyl)isoxazoles afford 2-aryl/alkyl-5-aryl/alkyl/methoxycarbo

48 urine BIIB021, and the resorcinylic pyrazole/isoxazole amide compounds VER-49009, VER-50589, and NVP-

49 operties of NVP-AUY922, a novel resorcinylic isoxazole amide heat shock protein 90 (HSP90) inhibitor.

50 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) glutamate receptors across the lifespan

51 A library of isoxazole and 1,2,4-oxadiazole-containing diheterocyclic

52 The terminal isoxazole and benzyl rings bind into distinct relatively

53 cloaddition strategy to append five membered isoxazole and isoxazolone as new phytochemical entities

54 parameters, as demonstrated for a library of isoxazole and pyrazole derivatives.

55 r isosteric replacement of alkyl-substituted isoxazole and pyrazole was shown by the synthesis of flu

56 Two series of saccharin/isoxazole and saccharin/isoxazoline hybrids were synthes

57 ways under VNS conditions, one leading to an isoxazole and the other resulting in the formal cyclopro

58 tituted isoxazole was then conducted with 56 isoxazole and triazole derivatives prepared using "click

59 ccess to stable MIDA boronate-functionalized isoxazoles and triazoles and their subsequent efficient

60 thiophene, furan, pyridine, indole, oxazole, isoxazole, and benzoxazole, are effective in this chemis

61 pyridines, imidazoles, oxazoles, thiazoles, isoxazoles, and pyrazoles.

62 chromenes to o-hydroxybenzylated pyrazoles, isoxazoles, and pyridines has been demonstrated.

63 which the central furan ring is replaced by isoxazole-and 42 novel analogues were prepared by two ge

64 3,5-Disubstituted isoxazoles are obtained in good yields by a convenient o

65 A variety of trisubstituted isoxazoles are prepared in moderate to excellent yields.

66 ed isomerization of the so-formed mixture of isoxazole/azirine-substituted biacetylenic intermediates

67 of cell or tissue lysates to a biotinylated isoxazole (b-isox) chemical precipitated hundreds of RNA

68 s and human cell lysates with a biotinylated isoxazole (b-isox) chemical.

69 and SAR of a potent and selective series of isoxazole based full agonists of S1P1.

70 An isoxazole-based alkylating agent was developed to select

71 The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads fo

72 dy, we have continued our efforts to develop isoxazole-based anti-TB compounds by applying rational d

73 Other isoxazole-based pharmaceuticals are probably also metabo

74 t both compounds 5 and 10 do not give [3,2-c]isoxazoles but rather afford regioselectively [2,3-d]iso

75 ral elaborations of these highly substituted isoxazoles by SN Ar reactions and hydrogenolysis allows

76 r of uracil polyoxin C (UPOC) with activated isoxazole carboxylic acids.

77 A phenyl dimethyl isoxazole chemotype resulting from a focused fragment sc

78 c RORgammat inverse agonists with a distinct isoxazole chemotype.

79 5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI) has been identified as a PAM selective

80 proven general with a range of carbenoid and isoxazole components and represents a unique disconnecti

81 Starting from compound 1, an isoxazole compound with potent AM2-S31N channel blockage

82 The isoxazole compounds have promising pharmacokinetic prope

83 y to investigate the effects of one of these isoxazole compounds, WJ352, on the conformation of the S

84 select resistance against a newly developed isoxazole-conjugated adamantane inhibitor that targets t

85 uinoline-based anti-TB compounds, bearing an isoxazole containing side-chain.

86 lore the structure-activity relationships of isoxazole-containing AM2-S31N inhibitors.

87 A range of isoxazole-containing amino acids was synthesized that di

88 Affinities of the isoxazole-containing peptides are comparable to those of

89 reaction routes on substituents at starting isoxazole core and reaction conditions are discussed on

90 o(-bromo or -methyl)furan-2-yl groups on the isoxazole core was essential for their selectivity towar

91 ble, and the thermodynamic 3,5-disubstituted isoxazole could be obtained by isomerization of its 3,4-

92 caffold Hsp90 inhibitor CNF2024/BIIB021, the isoxazole derivative VER-52296/NVP-AUY922, and the carba

93 (PM226)], a selective and potent CB2 agonist isoxazole derivative, was tested in the acute phase of T

94 The 43 isoxazole derivatives were assayed against Trypanosoma b

95 lar library containing over 40 cycloalkane[d]isoxazole derivatives.

96 Muscimol is a psychoactive isoxazole derived from the mushroom Amanita muscaria and

97 1600-fold and only leads to formation of the isoxazole end product (the result of the transaminase pa

98 y, a new series of nAChR ligands based on an isoxazole-ether scaffold have been designed and synthesi

99 Cycloalkane[d]isoxazoles form new core structures that interact with t

100 rocyclic framework (the anthranil or benzo[c]isoxazole framework) is formed as the result of diversio

101 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate receptor subunit GluR2 in the nucle

102 hat K18, which contains a 3-(dichlorophenyl)-isoxazole group connected through carbonyloxycarboximida

103 Following the discovery that a 3-amino-isoxazole group displays significantly improved metaboli

104 uce a variety of dibenzosuberones bearing an isoxazole group in 24 to >99% (1)H NMR yields.

105 comparison to its 5-regioisomer, the 3-amino-isoxazole group was combined with the optimal 2'-substit

106 group and the carbon atom of the carboxyl or isoxazole group.

107 do-dig cyclization-alkenylation synthesis of isoxazoles has been developed.

108 A probable mechanism for the formation of isoxazoles has been suggested.

109 N,N-di-Boc imide-functionalized triazole and isoxazole heterocycles.

110 electrophiles, furnished the functionalized isoxazoles in good yields.

111 es but rather afford regioselectively [2,3-d]isoxazoles in good yields.

112 nitrostyrenes affords 4' H-spiro[indole-3,5'-isoxazoles] in a diastereomerically pure form.

113 yzed reactions to yield 3,4,5-trisubstituted isoxazoles, including valdecoxib.

114 ed to the identification of 3-amino benzo[ d]isoxazoles, incorporating a N, N'-diphenyl urea moiety a

115 The photochemistry of matrix-isolated isoxazole, induced by narrowband tunable UV-light, was i

116 rocess is presented, which directly converts isoxazoles into their oxazole counterparts via a photoch

117 Isoxazole is chemically attached to Si(111)-7 x 7 throug

118 zole-4-carboxylic acid derivatives by domino isoxazole-isoxazole isomerization is reported.

119 A practical synthesis of isoxazole/isoxazoline derivatives via Machetti-De Sarlo

120 based organocatalysis for the preparation of isoxazole/isoxazoline moieties in an environmentally ben

121 with alkynes/alkenes to afford a library of isoxazole/isoxazoline products.

122 ied a family of neurogenic 3,5-disubstituted isoxazoles (Isx) that increased expression of neurogenic

123 d 2-aminopyridines, imidazoles, oxazoles, or isoxazoles leads to the incorporation of the [B-C] motif

124 A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric re

125 rtant one involves the transformation of the isoxazole moiety into a carboxylic acid group, thus open

126 phenyl ring as well as the 5-position of the isoxazole moiety may allow for the development of more p

127 , we reported on a series of isoxazoline and isoxazole monobasic noncovalent inhibitors of factor Xa

128 oward either 3- or 5-fluoroalkyl-substituted isoxazoles or pyrazoles containing an additional functio

129 ndensation with benzamidoxime gave the final isoxazole-oxadiazole diheterocyclic product in good yiel

130 lecules containing two different heteroatoms isoxazole, oxazole, and thiazole on Si(111)-7 x 7 was st

131 ecules containing two different heteroatoms (isoxazole, oxazole, and thiazole) and of the aromatic mo

132 for the first time as an intermediate in the isoxazole-oxazole photoisomerization.

133 th hydrolytically stable, fused isoxazolone, isoxazole, oxazolone, or cyano substituents on the aroma

134 soxazole acid using HBTU or alternatively an isoxazole pentafluorophenyl ester.

135 stematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen re

136 indings, a detailed mechanistic proposal for isoxazole photochemistry is presented.

137 The isoxazole photoreaction starts to occur upon irradiation

138 was performed and further decoration of the isoxazole product was achieved.

139 oxygen on the electrophilic amine to produce isoxazole products, as compared to the previous reportsa

140 H]-MK-801, [3H]-2-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) or [3H]-kainate.

141 type of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor in mice disrupts th

142 king of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluA1 and

143 nalysis for alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor subunits GluR2 and

144 mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors (AMPARs) and is Ca

145 by NMDA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors in hippocampal pyr

146 hyperactive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors.

147 utamate and alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate (AMPA)) and a partial agonist (kain

148 family, namely, a-amino-3-hydroxy-S-methyl-4-isoxazole propionate (AMPA), kainate, and N-methyl-d-asp

149 erations to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-type glutamate receptors cau

150 ate binding alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate and kainate subtypes of the ionotro

151 ion of the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionate receptor (AMPAR) subunit 1 (GluR1),

152 ha and the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionate receptor subunit GluR1.

153 plasticity, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors (AMPA-Rs) with an electro

154 ts of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) glutamate receptors in the nucleus

155 it of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor mediates two dynamic chan

156 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, in cerebral cortex, und

157 olution the alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate-bound form of this mutant exists pr

158 rtate-type, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-type, and metabotropic-type glutama

159 e glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate/kainate receptor antagonist CNQX (0

160 alpha-Amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors mediate excitatory

161 ters of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors or the postsynapti

162 In alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors, RNA editing and a

163 motoneuron alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptors.

164 increased alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) throughput.

165 receptors, alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), and N-methyl-d-aspartic aci

166 regulated alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)-induced GluR1 and GluR2 inte

167 NMDAR) and alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor (AMPAR) are ionotropic glu

168 reases the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor (AMPAR)-mediated contribut

169 /NR2b) and alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPA-R) (GluR1/GluR2) se

170 ediated by alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) and N-methyl-d-a

171 -permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) in the lateral a

172 osition of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) is an important

173 mplex with alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs), the major excit

174 containing alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (GluR1-AMPARs) are implic

175 -permeable, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors.

176 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate) recep-tors desensitize rapidly and

177 tion, AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate)-preferring and kainate (KA)-prefer

178 subunits of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate-preferring, kainate-preferring, and

179 , acting at alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) -selective and kainate-s

180 tio between alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-methyl-D-aspartate

181 VGCCs), the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) class of glutamate recep

182 competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) glutamate receptor antag

183 ceptors for alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) in the nucleus accumbens

184 ocked by the alpha-amino-3-hydoxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist 6-ni

185 ansmembrane alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor regulatory prot

186 full-length alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionic acid (AMPA) receptor structure (1).

187 ulations of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-active and inac

188 r 3 (GluR3) alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (WT GluR3) and

189 e number of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are proportion

190 by blocking alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors impaired both

191 ribution of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors to the control

192 ors of the alpha-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid (AMPA) subtype and has been lin

193 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtypes of glutamate re

194 morphology, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) to N-methyl-D-aspartate

195 ture of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-sensitive, homotetrameri

196 lization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

197 hibition of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

198 alpha-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

199 Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

200 A)-type and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors

201 alate), and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA).

202 Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate recept

203 asticity of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid and N-methyl-D-aspartate recept

204 1 and GluA2 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) and GluN1 N-me

205 ly modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) clustering and

206 (NMDAR) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) properties to

207 tion of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) subunit, GluR1

208 hippocampal alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) trafficking, a

209 tagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR).

210 cts require alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor activation and are blo

211 a glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonist.

212 but not the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunit GluR2, were co

213 s of AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor)-mediated currents fol

214 ation of an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor-positive modulator imp

215 -permeable) alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPAR) in the hippoc

216 The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) are glutamat

217 -containing alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) in spines.

218 )-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) in the hippo

219 , including alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), are believe

220 ostsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs).

221 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs).

222 )-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (CP-AMPARs).

223 NMDAR but not alpha-amino-3-hydroxy-methyl-4-isoxazole propionic acid receptors was also increased.

224 of AMPARs (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors).

225 Glutamate, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with cyclothiazide, and thapsig

226 tor agonist alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with high affinity.

227 ffinity AMPA (alpha-amino-3-hydroxy-5-methyl isoxazole propionic acid) and kainate glutamate receptor

228 d rat AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptor subtypes

229 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) glutamate receptor (AMPAR).

230 f the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor subunit GluA1.

231 o of AMPA (alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid) receptor- to NMDA (N-methyl-d-

232 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors (AMPARs), activated

233 on of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, a subtype of glutam

234 aptic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, thereby strengtheni

235 ce of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors.

236 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors.

237 tion of AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid)-receptor-mediated currents at

238 uced an AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole propionic acid)-receptor-mediated increase in

239 of an AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-subtype iGluR in explicit wate

240 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-subtype ionotropic glutamate r

241 ereas AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate receptor subunits were

242 eable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate receptors alone or by

243 unit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptor, Ser94

244 lization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors (AMPAR

245 (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid.

246 signals to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid.

247 phology and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/N-methyl-D-aspartate glutamate

248 ses in both alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/N-methyl-D-aspartate glutamate

249 intra-NASh alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/N-methyl-D-aspartate receptor t

250 receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; AMPA-Rs) purified from rat bra

251 delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic-type receptors (AMPARs) to synapses,

252 The (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole) propionic acid (AMPA) receptor discriminates

253 nists on (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole) propionic acid (AMPA) receptors but neverthel

254 The (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazole)propionic acid (AMPA)-subtype glutamate recept

255 NR2A/B) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) (GluR1 and GluR2) subuni

256 tor and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor in the dorsal,

257 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors is implicated

258 ferences in alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunit expres

259 gulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunits in th

260 function of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors, and, more recently,

261 subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors.

262 partate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) and metabotropic glutamate (mG

263 icostriatal alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid-type glutamate receptor-mediate

264 ng to NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole-proprionate (AMPA), and kainate receptors in b

265 unit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor failed to reve

266 n inhibited alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptor-mediated synap

267 tion of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA)/KA receptor agonist KA

268 anide Michael addition/methylation/reductive isoxazole-pyrrole transformation" is developed.

269 onformation generally seen with the pyrazole/isoxazole-resorcinol class of inhibitors.

270 ituted 1,2,3-triazoles and 3,4-disubstituted isoxazoles, respectively.

271 This study revealed that while the isoxazole ring can be replaced by a triazole system, the

272 hilic side chains at the C-5 position of the isoxazole ring have been prepared.

273 (6) as the catalyst can easily transform the isoxazole ring into the beta-aminoenone group.

274 ion reaction was developed, allowing for the isoxazole ring opening and global deprotection to be ach

275 its active metabolite teriflunomide through isoxazole ring opening has been monitored in vitro using

276 ed aldehyde, aminocarbonyl, cyano groups, or isoxazole ring) with thiol salts were investigated.

277 We also identify an isoxazole ring-containing small molecule, previously sho

278 mode involving Mo(CO)(6)-mediated reductive isoxazole ring-opening, Mo(CO)(6)-catalyzed cis-trans-is

279 which have no substituent on the 2beta-(1,2-isoxazole) ring, all compounds were selective for the DA

280 tion of "atom replacement" mimetics in which isoxazole rings linked by thioethers mimic the alternati

281 carboxylic acid moiety onto a trisubstituted isoxazole scaffold.

282 d as the reduced and isomerized forms of the isoxazole SMX moiety.

283 n the synthesis of 5-fluoroalkyl-substituted isoxazoles starting from functionalized halogenoximes is

284 Isoxazole stimulates myofibroblast differentiation via i

285 ip (SAR) analysis revealed that the aromatic isoxazole substituent in the southern part regulates the

286 ime in the presence of bleach) to afford the isoxazole-substituted carboxylic acid methyl ester.

287 The ED(50) values for 2beta-(1,2-isoxazoles) that caused locomotor stimulation ranged fro

288 aldehydes are converted to fused tetracyclic isoxazoles through a synthetic sequence incorporating su

289 the domino isomerization, transformation of isoxazole to 2H-azirine, which is compatible with Ph3PAu

290 lieu of an alkene leads to the formation of isoxazole under identical reaction conditions.

291 zirines isomerize quantitatively either into isoxazoles under catalytic conditions (dioxane, 105 degr

292 approach for the synthesis of functionalized isoxazoles via palladium-catalyzed cascade annulation/al

293 = 221 nm, in addition to this decomposition, isoxazole was also found to isomerize into several produ

294 ationship analysis of this 3,5-disubstituted isoxazole was then conducted with 56 isoxazole and triaz

295 ds based on amantadine- and aryl-substituted isoxazole were discovered to inhibit the S31N channel ac

296 d in two steps from the corresponding [2,3-d]isoxazole, which is interesting from the perspective of

297 hira coupling of 5-methoxy-4-(prop-2-yn-1-yl)isoxazoles with 6-bromonicotinates to give methyl 6-(3-(

298 nton reaction of 5-methoxy-4-(prop-2-yn-1-yl)isoxazoles with Cu(OAc)(2), followed by Fe(NTf(2))(2)/Au

299 carboxylic acids (imidazo[1,2-a]pyridine and isoxazole) with aryl halides.

300 lucuronidated less than previously described isoxazoles, yielding higher drug levels in human cancer